Abstract
Introduction

73
Apolipoprotein D (ApoD) is a Lipocalin widely expressed in mammalian tissues and 74 known to bind a series of hydrophobic ligands in vitro with high affinity 75 (pregnenolone, progesterone and arachidonic acid) [1] [2] [3] as well as cholesterol with 76 very low affinity [4] . The expression of ApoD is prominent in the nervous system, 77 particularly upon aging or induced damage. We have shown that it exerts protective 78 roles in both situations: by controlling the levels of brain peroxidated lipids in a model 79 of accelerated aging by oxidative insult [5] , or by controlling the extent and duration 80 of inflammatory processes after peripheral nerve injury [6] , influencing this way the 81 rate of nerve regeneration. 82
Curiously, ApoD was simultaneously discovered in the human breast cyst fluid and 83
as an apolipoprotein present in high-density lipoproteins (HDL) and to a lesser extent 84 in very low-density lipoproteins (VLDL) [7, 8] . ApoD is an atypical apolipoprotein, 85 unrelated to other apolipoproteins in both structure and evolutionary origins [9] . 86
Because ApoD is mainly located in HDL, it was soon proposed to have a role in lipid 87 homeostasis [10] . 88
The Drosophila genome contains two Lipocalin homologues of vertebrate ApoD, Glial 89 Lazarillo (GLaz) and Neural Lazarillo (NLaz), mainly expressed in glia and neurons 90 
Methods
121
Ethical approval
Experimental Animals 127
WT and ApoD-KO mice were bred at the animal facility of the University of Valladolid, 128
Spain. ApoD-KO mice were generated and genotyped as previously described [5] . 129
Mice were fed standard rodent chow and water ad libitum in ventilation-controlled 130 cages in a 12 h-light/dark cycle. The experimental cohorts used in this study were 131 males of the F1 generation of homozygous crosses. The parental generation was 132 composed of ApoD-/-and ApoD+/+ littermates from heterozygous crosses of the 133 ApoD-KO line in C57BL/6 background. This strategy avoids the potential maternal 134 effects of ApoD and generates wild-type and ApoD-KO cohorts with a homogeneous 135 genetic background. Two independent cohorts were used for the collection of tissues 136 at two ages: 3 months (n=10/genotype) and 21 months old (n=11/genotype). 137
Plasma Biochemistry 138
Blood samples were obtained from mice under fasting conditions (16 hours) or under 139 non-fasting conditions (animals had free access to food pellets ad libitum for 48 h 140 after the fasting period). This paradigm compares fasting versus non-fasting 141 conditions, since the exact timing of food intake with respect to sample collection is 142 not determined. Blood was collected from the tail vein into capillary tubes precoated 143 with potassium-EDTA (Sarstedt, Nümbrecht, Germany) for the preparation of plasma. 144
Blood glucose levels were determined using a Glucometer Xceed (Abbott Diabetes  145 Care Ldt., Oxon, UK). Plasma triglycerides and cholesterol levels were determined 146 using the Wako triglyceride and cholesterol reagents (Wako Chemicals GmbH, 147
Neuss, Germany). Plasma insulin levels were measured using ultrasensitive mouse 148 ELISA (ALPCO Diagnostics, NH, USA). 149
Food intake 150
For food intake determination, ApoD-KO and WT mice were separated in individual 151 cages (n=7-11 mice per genotype). After the 16 h fasting period, food pellets (50 g) 152 were added to each cage, and food intake of each mouse was estimated from the 153 difference in remaining food weight at 24 and 48 h. These weights were averaged to 154 provide an estimate of the mean food intake of each genotype in the 48 h period 155 following fasting. 156
Glucose tolerance test and insulin sensitivity index 157
Mice were fasted for 16 hours and injected intraperitoneally with glucose at 2g/Kg of 158 body weight. Blood glucose levels were determined and plotted as a function of time. 159
Insulin sensitivity index (ISI) was calculated using the formula ISI= 2/[(INSXGLU)+1], 160 where INS is fasting plasma insulin levels and GLU is fasting blood glucose levels 161 with values converted to pmol/L and mmol/L respectively [20] . 162
Hepatic triglyceride determination was performed as previously described [14] . For 164 liver histology, standard paraffin and cryostat sections were performed after fixation 165 in 4% paraformaldehyde as previously described [6] . Oil-red O staining was 166 performed on 10 µm cryostat sections using isopropanol as diluent. Hematoxilin-167
Eosin staining was performed on 3 µm paraffin sections following standard 168
procedures [6] . 169
Determination of islet mass and islet histomorphometry 170
Pancreata were excised, fixed, sectioned, stained with insulin, and quantitative islet 171 histomorphometry was performed as previously described [21] . 172
Immunoblot analysis 173
To determine the effect of ApoD deficiency on LPL protein expression, epididymal fat 174 tissue was collected from experimental and control mice. 
Statistical analysis 185
Statistical analyses of data were performed by Student-t test and by analysis of 186 variance (ANOVA). Data were expressed as mean ± SD. P values <0.05 were 187 considered significant. 188
Results
189
Effect of ApoD deficiency on triglyceride metabolism in mice 190
We reported that elevated ApoD production resulted in significant reduction in 191 plasma TG levels in mice [14] . Here, we determined the impact of ApoD on 192 triglyceride metabolism in the ApoD knockout mice (ApoD-KO). When compared to 193 control, non-fasting ApoD-KO mice exhibited significantly increased TG levels at 3 194 and 21 months of age (Fig. 1A) . In contrast, fasting plasma TG levels remained 195 unchanged (Fig. 1A) . Whereas ApoD deficiency reduced plasma cholesterol levels in 196
ApoD-KO mice at 3 months of age, this reduction was not observed at 21 months of 197 age ( Fig 1B) . In addition, ApoD deficiency resulted in a significantly increased food 198 intake at 3 months of age ( Fig. 1C ) without differences in body weight (Fig. 1D) . 199
However, food intake and body weight at 21 months remained unchanged ( we determined blood glucose and insulin levels in ApoD-KO and control mice. When 222 compared to control, ApoD-KO mice exhibited similar fasting and non-fasting blood 223 glucose levels (Fig. 4A ). However, non-fasting plasma insulin levels were significantly 224 elevated in ApoD-KO mice (Fig. 4B) . To evaluate the impact of ApoD deficiency on 225 whole-body glucose disposal rates, glucose tolerance tests were performed. As 226 shown in Fig. 4C , similar glucose profiles were observed in ApoD-KO and control 227 mice in response to intraperitoneal glucose infusion. However, ApoD-KO mice show 228 a trend to increase insulin release during the glucose tolerance test, although this 229 trend did not achieve statistical significance (data not shown). Based on fasting blood 230 glucose and plasma insulin levels, we calculated the insulin sensitivity index (ISI). As 231 shown in Fig. 4D , ApoD-KO mice exhibited similar ISI regardless of age. However, 232
ApoD-KO mice at 3 and 21 months of age were associated with increased non-233 fasting insulin:glucose ratio (Fig. 4E) , suggesting that ApoD deficiency is associated 234 with inappropriate hyperinsulinemia to maintain normoglycemia in non-fasting 235 conditions. 236
Insulin resistance usually precedes the development of glucose intolerance and type 237 2 diabetes. Before this happens, the pancreas compensates for insulin resistance by 238 increasing insulin secretion sustaining normoglycemia. Beta-cell compensation can 239 be accomplishing by increasing beta-cell mass or enhancing cellular secretory 240 capacity. To investigate why an ApoD deficiency leads to hyperinsulinemia, we 241 performed a histomorphometric analysis of beta-cell mass in ApoD-KO and control These findings suggest that the hyperinsulinemia observed in non-fasting ApoD-KO 245 mice was not due to beta-cell mass changes or growth, but related to beta-cell 246 function. 247
Discussion
248
In this study, we hypothesized that ApoD deficiency would increase plasma 249 triglyceride levels and could contribute to the pathogenesis of dyslipidemia. To 250
contrast this hypothesis, we tested whether mice lacking ApoD gene have elevated 251 plasma triglycerides levels. We show that ApoD deficiency is associated with 252 hypertriglyceridemia and decreased LPL protein levels in adipose tissue in non-253 fasting conditions. Consistently, we previously showed that elevated ApoD 254 production was associated with increased LPL activity in mice, contributing to 255 ApoD regulation in response to fat load has not been extensively studied. In support 276 of this notion, we showed that elevated plasma ApoD levels in diet-induced obese 277 mice was associated with reduced body weight and fat pad mass [14] . Here, we 278
show an age-dependent effect of ApoD deficiency on food intake and body weight. and type 2 diabetes [18, 29, 19] , and that circulating concentrations of ApoD are 326 reduced in obese mice [14] . In Drosophila, the genetic ablation of NLaz decreased 327 glycogen and glucose levels, whereas transgenic overexpression increased glucose 328 levels. Furthermore, NLaz function antagonizes the insulin/IGF signaling pathway 329 and is critical for the regulation of metabolic adaptations to stress [11] . In rodents, 330 transgenic overexpression of ApoD in mice is associated with normal non-fasting 331 blood glucose levels, hyperinsulinemia and glucose intolerance [15] . In this study, we 332
show that non-fasting ApoD-KO mice exhibit elevated triglyceride levels associated 333 with hyperinsulinemia and normoglycemia. The higher insulin levels and 334 insulin:glucose ratio in ApoD-KO mice suggest that they are insulin resistant. 335
Noteworthy, ApoD-KO and WT mice exhibited similar glucose tolerance. Thus, in our 336 model system a more sophisticated and sensitive technique, such as the 337 hyperinsulinemic euglycemic glucose clamp, should be used to quantify insulin 338 sensitivity. Interestingly, hypertriglyceridemia under non-fasting conditions is usually 339 a characteristic associated with the development of insulin resistance [30] . 340
The fact that hyperinsulinemia in ApoD-KO mice is not accompanied by 341 hypoglycemia may indicate a pancreatic beta-cell compensatory mechanism to 342 overcome insulin resistance. However, the observed hyperinsulinemia was not 343 accompanied by changes in islet morphology, total beta-cell mass, beta-cell volume 344 or islet number, suggesting that ApoD deficiency does not alter beta-cell growth. Manuscript METABOLISM-D-11-00018R1. Genetic deficiency of Apolipoprotein D in the mouse is associated with non-fasting hypertriglyceridemia and hyperinsulinemia.
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